Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flavia Longo

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Journal of Cancer Research and Clinical Oncology|February 20, 2017
Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE studyMaria Rita Migliorino, Antonio Santo, Giampiero Romano, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 17, 2010
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapyFlavia Longo, Giovanni Mansueto, Vittoria Lapadula, et al.
Clinical Lung Cancer|May 10, 2011
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutationsGabriella Farina, Flavia Longo, Olga Martelli, et al.
Oncotarget|September 30, 2015
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyMirko Marabese, Monica Ganzinelli, Marina C Garassino, et al.
The Lancet. Oncology|July 26, 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialMarina Chiara Garassino, Olga Martelli, Massimo Broggini, et al.
Clinical Breast Cancer|December 3, 2014
Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian surveyNicola Tinari, Caterina Fanizza, Marilena Romero, et al.
Scientific Reports|November 18, 2015
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)Monica Ganzinelli, Eliana Rulli, Elisa Caiola, et al.
Communications Biology|February 27, 2020
Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigensAlessio Grimaldi, Ilenia Cammarata, Carmela Martire, et al.
Cancers|January 30, 2019
A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal CancerCarlo Capalbo, Francesca Belardinilli, Domenico Raimondo, et al.
Scientific Reports|April 16, 2016
Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone MetastasesDaniele Santini, Sandro Barni, Salvatore Intagliata, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Journal of Cancer Research and Clinical Oncology|February 20, 2017
Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE studyMaria Rita Migliorino, Antonio Santo, Giampiero Romano, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 17, 2010
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapyFlavia Longo, Giovanni Mansueto, Vittoria Lapadula, et al.
Clinical Lung Cancer|May 10, 2011
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutationsGabriella Farina, Flavia Longo, Olga Martelli, et al.
Oncotarget|September 30, 2015
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyMirko Marabese, Monica Ganzinelli, Marina C Garassino, et al.
The Lancet. Oncology|July 26, 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialMarina Chiara Garassino, Olga Martelli, Massimo Broggini, et al.
Clinical Breast Cancer|December 3, 2014
Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian surveyNicola Tinari, Caterina Fanizza, Marilena Romero, et al.
Scientific Reports|November 18, 2015
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)Monica Ganzinelli, Eliana Rulli, Elisa Caiola, et al.
Communications Biology|February 27, 2020
Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigensAlessio Grimaldi, Ilenia Cammarata, Carmela Martire, et al.
Cancers|January 30, 2019
A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal CancerCarlo Capalbo, Francesca Belardinilli, Domenico Raimondo, et al.
Scientific Reports|April 16, 2016
Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone MetastasesDaniele Santini, Sandro Barni, Salvatore Intagliata, et al.
Pageof 8